ProNAi Therapeutics Inc. (DNAI) Announces Earnings Results, Misses Expectations By $0.21 EPS
ProNAi Therapeutics Inc. (NASDAQ:DNAI) announced its quarterly earnings results on Thursday. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.21.
Shares of ProNAi Therapeutics (NASDAQ:DNAI) opened at 1.50 on Friday. The stock has a 50 day moving average of $1.70 and a 200-day moving average of $2.64. ProNAi Therapeutics has a one year low of $1.39 and a one year high of $19.50. The stock’s market capitalization is $45.49 million.
Separately, Zacks Investment Research raised shares of ProNAi Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Tuesday, October 11th.
Several institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new position in shares of ProNAi Therapeutics during the third quarter worth approximately $294,000. Panagora Asset Management Inc. acquired a new position in shares of ProNAi Therapeutics during the second quarter worth approximately $168,000. Bridgeway Capital Management Inc. acquired a new position in shares of ProNAi Therapeutics during the second quarter worth approximately $109,000. Pictet Asset Management Ltd. increased its position in shares of ProNAi Therapeutics by 957.9% in the second quarter. Pictet Asset Management Ltd. now owns 684,433 shares of the company’s stock worth $4,298,000 after buying an additional 619,733 shares in the last quarter. Finally, Ancora Advisors LLC acquired a new position in shares of ProNAi Therapeutics during the second quarter worth approximately $132,000. 35.26% of the stock is currently owned by institutional investors and hedge funds.
About ProNAi Therapeutics
ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.
Receive News & Stock Ratings for ProNAi Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProNAi Therapeutics Inc. and related stocks with our FREE daily email newsletter.